WASHINGTON, DC — The Biosimilars Council applauds the unanimous Senate passage of the Affordable Prescriptions for Patients Act led by Senator Cornyn (R-TX) and Senator Blumenthal (D-CT). The bill is aimed at reforming patent abuse in the pharmaceutical industry.“The Biosimilars Council and AAM applauds unanimous Senate passage of the Cornyn-Blumenthal legislation,” said Craig Burton, executive director of the biosimilars council. “Patent thickets are used by brand pharmaceutical companies to maintain high prices and deny patients access to lower-cost medicines. This legislation is a great step in curbing these abuses and will help increase competition and access for biosimilars. We encourage the House to take up this legislation and for Congress to continue working to help lower costs for patients.”
Biosimilars Council applauds patent abuse act
The Biosimilars Council applauds the unanimous Senate passage of the Affordable Prescriptions for Patients Act led by Senator Cornyn (R-TX) and Senator Blumenthal (D-CT). The bill is aimed at reforming patent abuse in the pharmaceutical industry.
Latest
Walgreens’ Gates shares insights at exclusive retailmediaIQ breakfast
Rick Gates, Walgreens’ chief pharmacy officer and current NACDS chairman, kicked off the NACDS Annual Meeting with a retailmediaIQ-sponsored breakfast discussion.
CDR coverage of the 2026 NACDS Annual Meeting
Click here for CDR's coverage of the 2026 NACDS Annual Meeting in Palm Beach, with updates added to this story throughout the April 17–21 event.
Sam's Club continues scaling MAP into a Retail Experience Network
Sam’s Club is expanding its Member Access Platform into a full-funnel retail media network.
A&G selling 78 Walgreens properties nationwide
The prime retail locations in high-traffic shopping corridors are available for direct lease, sublease or sale.